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THE success of any form of cancer
therapy must depend on those features
of a tumour which distinguish it from
normal tissue. The overall failure of
modern cancer treatments to control
disseminated disease reflects their lack of
selectivity, the absence of truly specific
target sites in the malignant cell and the
consequent inability to discriminate
between normal and malignant states. It
is in this context that an immunological
approach to cancer treatment provides
suchanattractive concept. The detection
of tumour associated antigens capable of
eliciting specific reactions in the patient
provides a rational basis for immuno-
therapy. Such an approach to treat-
ment, albeit hypothetical, would seem to
possess high specificity, immunological
attack being directed at only those cells
expressing the tumour antigens, thus
sparing normal cells from damage.
This review will be restricted to clinical
attempts to use immunological methods
in the treatment ofhuman cancer. Many
unrelated treatment methods may well
have inadvertently utilized immunological
phenomena: e.g., Coley's toxin (see review
by Nauts, Swift and Coley, 1946) may
have immunological effects on the patients
apart from its direct toxic action on the
tumours. There is an unfortunate ten-
dency to regard any procedure involving
treatment with tissue extracts as immuno-
therapy.
Evidence for the existence of tumour-
associated antigens in animal systems
and of host reactions to them is now vast
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and convincing. A reviewofthisevidence
is outside the scope of the present com-
munication but excellent articles by
Southam (1960), Old and Boyse (1966)
and Klein, G. (1968a) summarize the most
compelling experiments on this subject.
The demonstration of tumour antigens
in experimental animals is a relatively
simple procedure, thanks to the develop-
ment of highly inbred strains. Removal
of an established tumour or immunization
with irradiated tumour cells will increase
resistance to tumour challenge in most
cases. Such an approach is obviously
impossible in man. Consequently, the
role of immunological mechanisms in host
resistance to human cancer remains to
be clarified, but there are some pointers
from the recent literature suggesting
that some human tumours do possess
antigens capable of eliciting immune
reactions in the patient, and that these
reactions may well be a crucial factor in
the natural history of malignant disease
in man (Klein et al., 1966; Morton et al.,
1968; Fridman and Kourilsky, 1969;
Hellstrom et al., 1971).
In the latter two decades of the last
century the recognition of immunity to
bacterial infections led to the postulate,
based at that time on inadequate data,
that tumours did possess distinct antigens
capable of eliciting host reactions. All
animal experiments performed at this
time involved the use of transplantable
tumours in randomly-bred or recently
captured wild animals. The absence of
inbred strains of experimental animalsG. A. CURRIE
TABLE I.-Potential Methods of Immunotherapy
Specific
Passive . Xenogeneic or allogeneic
anti-tumour antisera
Adoptive Xenogeneic or allogeneic
sensitized lymphoid cells or
extracts
Active . Tumour cells, extracts or
chemically-modified tumour
antigens. Foetal antigens
invalidated all these experiments as the
resistance of an animal to a transplantable
tumour contained an element of allograft
rejection. This problem was not recog-
nized at the time and as a result of appar-
ently promising animal experiments, many
groups of clinicians attempted to employ
a variety of immunological manoeuvres
as " magic bullets " for the treatment of
patients with advanced disease. From
1880 onwards a wave of enthusiastic
cancer treatments with vaccines and sera
swept across Europe from its apparent
inception in Germany. These very early
attempts were poorly documented and
today remain mostly anecdotal, the first
adequate series being described in 1895.
The potential methods of tumour
immunotherapy can be subdivided for
ease of discussion into 6 main groups
(Table I).
SPECIFIC ACTIVE IMMUNOTHERAPY
The first series of patients treated by
specific active immunotherapy was des-
cribed in 1902 by von Leyden and
Blumenthal. These authors used an auto-
logous tumour cell suspension as the
vaccine and treated patients suffering
from advanced metastatic disease. No
clear-cut evidence of objective improve-
ment was detected as a consequence
of the administration of this vaccine
despitesomeslightsubjectiveimprovement
in 2 cases. In 1909, however, Le Bertrand
described one case of objective tumour
regression following treatment with a
similar autologous tumour cell vaccine.
In the same year Coca and Gilman (1909)
reported several cases of regression and
Non-specific
Non-specific serum factors
Properdin, etc.
Normal lymphoid cells
allogeneic or xenogeneic. Anti-
tumour effect of GVH disease
Non-specific stimulants of the
immune response BCG,
C. parvum, etc.
attributed them to the use of this vaccine.
Also, in 1909 von Dungern injected
patients with their own emulsified tumours
and noticed the production ofoedema and
reddening at the injection site. He
regarded this reaction as specific because
it occurred only when autologous tumours
were injected. Allogeneic tumour mater-
ial produced no such effect.
Following these brief and moderately
encouraging reports Coca, Dorrance and
Lebredo (1912) investigated a much
larger series of patients with an assort-
ment of advanced malignant tumours.
Their vaccine treatment consisted of
large quantities (3-15 g) of macerated
tumour repeatedly administered at 14-day
intervals. This " vaccine " preparation
was reported to contain large numbers
of living tumour cells. It is interesting
to note that they encountered only one
instance of tumour implantation at the
injection site. Out of a total of 79
patients, 39 received autologous tumour
and 48 received allogeneic (i.e. material
from other patients) vaccine (several
receiving both types). The results were
complex and difficult to assess. Five
patients, all treated with an allogeneic
vaccine, demonstrated unequivocal objec-
tive regression. Of these, 2 developed
fever and abscesses at the injection sites
and consequently tumour regression might
be attributed to the effects of bacterial
toxins and/or fever (Nauts, Swift and
Coley, 1946): 2 were cases of epidermal
carcinoma which underwent ulceration
following liquefaction necrosis (a not
uncommon spontaneous event in this
type of lesion), and only in one case, a
scirrhous breast carcinoma, could tumour
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regression be attributed solely to the
vaccine and the regression lasted only 4
months. In other words, only one case
out of 79 showed any objective clinical
benefit from active immunization with
tumour tissue and that was temporary.
Coca and his colleagues were forced to
conclude that " active immunization
against malignant tumours in man is
impracticable ".
In 1911, Risley, encouraged by the
earlier, more optimistic, report from
Coca and Gilman (1909) on their results
obtained at the Philippine General Hos-
pital, treated 20 patients by active
immunization with a tumour cell vaccine.
His vaccine was similar to that of Coca
and Gilman except that he employed
a rather more vigorous maceration, the
resulting vaccine being a tumour extract
which was administered as 50 ml injec-
tions, usually every 14 days. Again,
he divided his patients into 2 groups, one
receiving autologous vaccine and the
other allogeneic extract. He described
each case in detail and concluded that
there was no evidence oftumour regression
in either of the groups; in fact Risley
alleged that the vaccine had caused
" increased activity on the part of the
cancer cells ", although his evidence to
support this somewhat frightening allega-
tion was far from convincing. Pinkuss
(1913) then reported 7 cases (all women)
with either breast or uterine tumours,
3 with post-surgery recurrences and 4 who
were inoperable. These patients were all
given a phenolized autologous tumour
vaccine and although the results were not
conclusive in objective terms, this author
was much in favour of a combined
therapeutic approach, advocating radical
surgery and vaccine treatment used to-
gether. Vaughan (1914), working in
Detroit, published a series of 100 patients
treated with both active and passive
immunotherapy. The active treatment
was again a tumour extract and the
resulting residue often given intraperi-
toneally, while the passive treatment
consisted of the use of sheep and rabbit
anti-tumour sera. There were no control
cases and for assessment of the effects we
have to rely on Vaughan's impressions.
He was obviously an enthusiast and gave
rather muddled figures for the incidence of
regression. However, from his descrip-
tions it is obvious that some regressions
must have occurred. In one group of his
advanced cases treated with surgery and
active immunization he claimed that 73
per cent showed some degree of clinical
benefit. One comment from his paper
merits special attention in view of modern
opinion. He stated that " the best results
are obtained in cases in which the amount
of tumour tissue present is small, and in
which the differential leucocyte count of
the patient shows a decided reaction
following administration of the cancer
protein ".
At the Middlesex Hospital in 1922,
Kellock and his group described a series
of 12 patients treated by the injection
of autologous tumour fragments into the
anterior abdominal wall. The authors
were unable to demonstrate any therapeu-
tic effect ofthis procedure on the course of
the disease. One major advance in their
work was the use of x-irradiation to
reduce the risk of tumour growth at the
implantation site. Many attempts at
immunotherapy at this time were, in
the light of present knowledge, extremely
bizarre. In one series (Rubens-Duval,
1932) patients with advanced disease
were treated unsuccessfully with homoeo-
pathic doses of an extract oftumour tissue
following extensive degradation and
extraction.
Many workers have, however, con-
tinued to examine the possible use of
tumour cells or simple extracts as a form
of active immunotherapy and every few
years another burst of enthusiasm has
resulted in the publication of further
extensive series. Graham and Graham
(1959) have described their use of auto-
logous vaccines in the treatment of
patients with gynaecological tumours.
They used their immunization techniques
in 232 cases (Graham and Graham, 1962)
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and their concluding sentence merits
repetition: " We conclude that auto-
genous vaccines can be given to patients
with little risk but that they fail to alter
the course of the disease with sufficient
regularity to recommend their use as treat-
ment ". They had, however, observed in
their 1962 paper that administration of
the vaccine to patients in whom the
bulk of the tumour had been surgically
ablated, had appeared to radiosensitize
the residual disease.
In 1960, Finney, Byers and Wilson
reported 9 patients treated for a variety
of malignant tumours by intramuscular
injection of a tumour homogenate in
Freund's adjuvant in order to assess
both its therapeutic and immunological
effects. The vaccine was given initially
in 3 doses on alternate days and then
repeated several weeks later. A rise in
" anti-tumour " antibodies was detected
in all the patients so treated, and injection
of these purified antibodies into sub-
cutaneous tumournodules causeddramatic
temporary regressions. However, the
elevation of such antibodies was also
induced by radiotherapy and the evidence
that these were tumour specific was far
from convincing.
In 1967, Czajkowski and his colleagues
described a method of chemically coupling
rabbit gamma globulin to human tumour
cells in an attempt to increase their
immunogenicity. Their preliminary
results were promising and were exten-
sively followed up by Cunningham and his
group (1969). These workers treated 42
patients with assorted cancers, by active
immunization with rabbit globulin-com-
plexed autologous tumour cells. Only
one patient showed any evidence of
regression and the authors failed to
detect delayed hypersensitivity to tumour
antigens in any of the treated cases.
They noted in passing that the procedure
was safe and that they could find no
evidence of tumour growth enhancement.
Subcellular tumour extracts were used
as a vaccine by Hughes and his co-
workers (1970) and this " antigen " pre-
paration was combined with adjuvants
such as pertussis vaccine, TAB and com-
plete Freund's adjuvant. Of 20 patients
receiving vaccine treatment 13 showed no
response at all, 2 had some degree of
subjective response, 4 demonstrated mar-
ginal improvement and only one case
could be described as having a clear-cut
objective response. It was also shown
that the use of the vaccine would in some
cases evoke cell-mediated immune reac-
tions to the tumour extract detected by
delayed hypersensitivity skin reactions
and that the use of the vaccine was a safe
procedure.
Humphrey and his colleagues (1971)
have combined immunization with a
crude tumour vaccine, with subsequent
exchange of plasma and white cells
between pairs of patients. In this series,
one of many from these authors, 38
patients received this form of treatment.
The pairs of patients did not necessarily
have tumours of similar histological type.
Eight patients were alleged to have shown
some form of objective improvement,
although it was transient in most ofthem.
Such a favourable result was said to be
associated with small inoperable primary
lesions, and aprolonged history of minimal
amounts of recurrent disease. There was
no way of distinguishing between the
effects of the immunization and the
adoptive cell transfer. The vaccine these
workers employed was a frozen-thawed
homogenate of tumour and its use was
not accompanied by any clinically appar-
ent deleterious effects.
While investigating the effect of
irradiated tumour autografts on patients
with malignant melanoma in an attempt
to investigate both humoral (Ikonopisov
et al., 1970) and cell-mediated (Currie,
Lejeune and Fairley, 1971) immunity, it
was shown that the use of such a cell
preparation as a vaccine was without
deleterious effects but that there was no
evidence of any clear-cut pattern of
therapeutic effect despite evidence to show
that the autoimmunization procedure
was capable of evoking both circulating
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antibodies and specifically cytotoxic
lymphocytes.
Recent specific active immunotherapy
has provided somewhat conflicting results
as to its value. In what is probably the
only randomized controlled trial of auto-
imnmunization with irradiated tumours so
far performed, Bloom and his colleagues
(personal communication) have treated a
series of patients with gliomata. Their
results indicate that the immunotherapy
procedure was certainly without any
beneficial effect on survival and may even
have shortened the mean survival time.
However, Powles and his associates have
recently shown (personal communication)
that frequent immunization with allo-
geneic irradiated leukaemic blast cells
appears to be capable of prolonging the
duration of remission in patients with
acute myeloblastic leukaemia. Such
studies emphasize the need for careful
design of controlled studies and that
under some circumstances immunothera-
peutic procedures may be harmful, while
under others they may be ofbenefit.
It must be emphasized that up until
now, specific active immunotherapy in
the form of tumour cell vaccines has
been used most extensively in patients
with advanced disease, often after the
failure ofconventional formsoftreatment.
Furthermore, in nearly all these clinical
reports it has been used alone and its
therapeutic value has been judged by that
criterion and found wanting.
It is clear that specific active immuno-
therapy with tumour cells or extracts
thereof is unlikely to be of benefit to
patients with advanced disease when used
as the only form oftreatment. However,
these rather pessimistic clinical reports
do not rule out the possibility that active
immunization withsuchvaccinesmaybeof
clinical value in patients with minimal
residual disease when combined with
other forms of treatment such as surgery,
irradiation or cytotoxic chemotherapy.
The feasibility of such a combined ap-
proach to therapywill bediscussed later in
this review.
SPECIFIC PASSIVE IMMUNOTHERAPY
As we have seen, specific active vaccine
treatment has a venerable history, but
specific passive immunotherapy, or sero-
therapy, is even older. In this form of
treatment experimental animals such as
sheep, rabbits, goats or horses were
immunized with fragments ofthe patient's
tumour and the resulting antiserum
either fractionated and then used, or
administered as whole serum. Perhaps
the earliest documented attempt at this
form of therapy is found in the French
literature. In 1895 Hericourt and Richet
published a brief note concerning sero-
therapy in the treatment of cancer.
They described 50 cases so treated and
claimed many beneficial effects, including
amelioration ofpain, diminutionin tumour
volume and general improvement in
health. They also remarked that this
serum treatment was generally without ill
effects. However, after the third or
fourth injection they often encountered
erythematous skin eruptions and in 4
cases the serum treatment caused tem-
porary unconsciousness ofunknown cause.
They asserted that normal animal serum
did not have any beneficial effects and
concluded that they were using a specific
immunological form of treatment. Their
summary stated that their serum treat-
ment was as yet oflittle value as a radical
anti-tumour therapy but that it was
better than any other form of treatment
available at that time.
Hericourt and Richet had employed
antisera raised in dogs and in doi*eys.
A goat anti-human malignant melanoma
serum was used in 1901 for the treatment
of 2 patients (Boeri, 1901) and was alleged
to have caused regression in both cases.
Vidal (1911-original not seen) reported
a large series of cases treated with anti-
tumour antisera. Massive regression was
found in 3 cases and some degree of
minor subjective improvement was repor-
ted for many more. In 1914 Berkeley
reported on 3 years' experiences with anti-
cancer sera. Eighty-nine cases were des-
cribed, 71 of which were evaluable; 32
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were suffering from inoperable disease.
No cures were obtained but some degree of
objective improvement was reported in
several. The remaining 39 patients had
primary tumours which were treated
surgically and the antisera were used as an
adjuvant therapy. No details were given
ofthe survival ofthis group but the overall
impression given by his description is
pessimistic.
In more recent years further series
have been described. Murray reported
(1958) over 200 patients treated with the
globulins from horses immunized with a
variety of human tumours. Despite the
high incidence of subjective improvement
and occasional objective changes in the
tumours, the series as described does not
provide any real basis for optimism con-
cerning the clinical value of this thera-
peutic approach. In 1959 Buinauskas and
hisgrouptreated 3patientswith carcinoma
of the breast with immune sheep gamma
globulin. Only minor changes in lymph
node metastases were detected.
The use of blood from patients whose
tumour has undergone spontaneous re-
gression has been described by Sumner
and Foraker (1960). The whole blood
from a case of regressed malignant melan-
oma was transfused into 2 patients with
widespread melanotic tumours. One of
these underwent a dramatic and long-
lasting regression. However, the use of
whole blood may well have involved adop-
tive transfer of cellular components of
immunological reactivity. Specific passive
immunotherapy has been attempted
in patients with Burkitt's lymphoma
(Ngu, 1967). Temporary tumour regres-
sion was reported following the adminis-
tration of serum from patients whose
tumours had regressed. However,
Clifford (1967) treated 2 patients in this
way, one ofwhom was unaffected whereas
the other showedincreasedtumourgrowth.
This form of therapy is also not
without its exponents of the bizarre.
Lewison and his colleagues (1960)
immunized cattle with human breast
tumours by injection into the udders of
pregnant cows. The colostrum was col-
lected for 7 days after parturition and
administered by mouth to the patients
whose tumours had been used for the
immunization. Not surprisingly, there
was no evidence of objective regression.
Antibodies are not absorbed through the
gut in early infancy.
Isoantibodies have occasionally been
used in the treatment of leukaemia.
Laszlo and his co-workers (1968) reported
lymphopenia and diminution of lymph
node size in 3 patients with chronic
lymphatic leukaemia so treated. The
isoantibodies were made by immunizing
volunteers with normal lymphocytes.
Normal sera were also administered and
were without any therapeutic effect.
Another approach has been by the use
of tumour-localizing antibodies as carriers
of some other therapeutic agent and has
been investigated in man by Day and his
colleagues (1957). Rabbit anti-glioma
antibodies were labelled with radio-
iodine (1251) and these workers were able
to show the localization of the label in the
tumours in situ several days after infusion
of the antibodies. There has as yet been
no evidence for any therapeutic effect.
Non-specific immunotherapy
By using a variety of manoeuvres,
it is possible to increase immunological
reactivity in a non-specific manner. One
early attempt to exploit such a pheno-
menonforthetreatment ofhumantumours
involved the use of reticuloendothelial
antisera. Based on the postulate that
very low doses of such an antiserum may
stimulate the target cells instead ofkilling
them, antisera were raised against the
components of the human reticuloendo-
thelial system and then administered in
very low doses to tumour-bearing patients,
In 1938, Fedyushin, working in the Soviet
Union, suggested that such an antiserum
hadclinicallydetectabletherapeutic effects
in man. Subsequently the reports of
Skapier (1947) and Davis (1957) claimed
some minorsubjectivebenefit butprovided
146EIGHTY YEARS OF IMMUNOTHERAPY
no objective evidence oftumour regression
following the use of such antisera.
A variety of biological agents are
known to stimulate the reticuloendothelial
system and to provide non-specific in-
creases in both cell-mediated and humoral
immunity to a variety of unrelated anti-
gens. Perhaps the most exciting and
provoking evidence for the potential
value of immunotherapy in human cancer
has been provided by Matheet al (1969) in
the treatment of acute lymphoblastic
leukaemia. The basis of their therapy is
the use of BCG (Bacillus Calmette-Guerin)
given into large skinabrasions and applied
very frequently. BCG is a powerful
non-specific immuno-stimulant capable
of inducing considerable resistance to
transplantable experimental tumours in
rodents. However, its role in Mathe's
series is unclear. The duration of
remission in his patients treated with an
immunotherapy protocol is undoubtedly
prolonged to an exciting degree. How-
ever, his patients also received irradiated
allogeneic leukaemic blast cells along with
many other agents including Poly I :Poly
C Corynebacteriumparvum andamantidine.
Thus, it is not possible to attribute his
clinical successes to any single approach
used in the protocol. The series does
not provide any evidence that BCG
alone is an effective or even useful thera-
peutic agent in the treatment of human
cancer. The results of the Medical
Research Council trial of the use of BCG
in acute leukaemia were very disappoint-
ing. There was no evidence that BCG
had any beneficial effects on duration of
remission. However, the BCG was used
as the sole immunological treatment and
it may be that the combination of such
an agent with, say specific active
immunization with leukaemic blast cells,
may provide a synergistic therapeutic
effect.
Another agent possibly more powerful
than BCG and under test in many centres
throughout the world is Corynebacterium
parvum. Effective in animal systems
this agent has undergone preliminary
testing by Halpern (1972) in a series of
cancer patients receiving combined cyto-
toxic chemotherapy. This agent and
similar bacteria obviously deserve close
scrutiny and possible therapeutic trial in
man. However, there is one major draw-
back to the use of bacteria and their
products in this form oftherapy. As they
are all potent immunogens they would
seem to be of value only as single-dose
agents. Repeated administration would
lead to powerful specific immunity and
consequently the immunological inactiva-
tion and destruction of the agent as
soon as it is administered. Thus, there
may be a need for a large panel of anti-
genically distinct agents for the sequential
treatment of a single patient.
SPECIFIC ADOPTIVE IMMUNOTHERAPY
The use of lymphoid cells in the
treatment of cancer patients is a relatively
recent development. It is based on the
demonstration of the central role of this
cell type in transplantation immunity.
Immune reactions to antigens which are
an integral part of the cell membrane,
as in the case of tumour cells, are usually
of the delayed hypersensitivity type, a
form of reaction which can be adoptively
transferred from one individual to another
with lymphoid cells.
The largest series of cases treated by
specific adoptive immunotherapy was
that described by NadlerandMoore (1969).
Their techniques consisted of cross-
immunization of pairs of patients with
tumour and subsequent exchanges of
their " sensitized " peripheral blood lym-
phocytes. A large number of patients,
mainly with malignant melanoma, were
treated by this method and occasional
regressions were recorded. No measure-
ments ofimmune reactions were made and
the overall series remains unconvincing
as a demonstration of a therapeutic effect
of immunotherapy. Andrews and his
colleagues (1967) had used a similar
approach on a much smaller series,
administering thoracic duct lymphocytes
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from patients immunized with tumour.
Using this method, they were able to
administer lymphocytes on a massive
scale. No therapeutic effects were detec-
ted in patients with melanoma or leukae-
miaandgraft-versus-host disease mayhave
supervened. Trouillas and Lapras (1969)
have employed autologous lymphocytes
from patients autoimmunized against
their own cerebral tumours. Thoracic
duct lymphocytes were injected into the
cerebrospinal fluid in a deliberate attempt
to by-pass the blood brain barrier. No
clinical evidence of benefit was forth-
coming but post-mortem examination of
the tumours showed massive lymphocytic
infiltration.
NON-SPECIFIC ADOPTIVE IMMUNOTHERAPY
The administration of large numbers
of non-sensitized lymphoid cells as a form
of therapy has been attempted in several
centres. When such cells are given in
large enough numbers they tend to induce
a graft-versus-host reaction (GVH) which
leads to the secondary syndrome. During
the development of the GVH reaction the
donor lymphocytes should also react tothe
host's tumour and mount a graft-versus-
tumour (GVT) reaction. Woodruff and
Nolan (1963) have treated 6 patients
suffering from advanced cancer by the
adoptive transfer of all the cells from one
human spleen injected intravenously over
one hour. Two patients, with intraperi-
tonealdissemination ofovarian carcinoma,
were given a similar number of cells into
the peritoneal cavity. All the patients
were pretreated with cytotoxic chemo-
therapy to inhibit the host's ability to
reject the donor cells. Some degree of
improvement, both subjective and objec-
tive, was detected in all 8 cases, ranging
from abolition of tumour ascites to the
relief of pain due to bone metastases.
However, the evidence that such responses
were a direct result of the spleen cell
infusion is far from convincing. Some of
the responses may well have been due to
theprior chemotherapy.
The treatment of leukaemia by total
ablation of the bone-marrow and recon-
stitution with allogeneic marrow is almost
always complicated by the development
of graft-versus-host disease, usually mani-
fested as the secondary syndrome. It has
beensuggestedbyMathe and his colleagues
(1965)thatthisGVH disease maywellhave
a potent anti-leukaemic effect. Following
the description of a 20-month remission
induced in a single case, Schwarzenberg
and his co-workers (1966) attempted the
non-specific adoptiveimmunotherapyof21
cases ofacute leukaemia by the infusion of
large numbers of leucocytes from patients
with chronic myeloid leukaemia. Most of
the cases ofacute leukaemiawere resistant
to chemotherapy andweregiven vastnum-
bers of leucocytes (up to 1012). Of the 21
patients so treated there were 9 remissions
ofwhich 6 were complete and 3 incomplete.
These remissions were allofshort duration.
Theauthorsconcludedthatthetherapeutic
effect was immunological but provided
little evidence to support this contention.
Symes and his co-workers (1968) have em-
ployed allogeneic and xenogeneic lympho-
cytes with and without prior sensitization
against the patient's tumour. This treat-
ment was combined with chemotherapy
and transient regressions were described.
Two patients who received sensitized pig
lymphocytes showed evidence of tumour
necrosis. However, the overall series
was not impressive as evidence for the
therapeutic value of specific and non-
specific adoptive immunotherapy. The
authors concluded that the results were
not good enough to warrant a therapeutic
trial.
OTHER APPROACHES TO IMMUNOTHERAPY
A novel form of so-called immuno-
therapy of tumours has been described by
Klein, E. (1968b) for the treatment of skin
and mucosal tumours. This consists of
promoting a delayed hypersensitivity
reaction to agents such as dinitrochloro-
benzene and then challenging the tumour
area with a dilute preparation of the
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sensitizing agent. The tumours them-
selves appear to be exquisitely sensitive to
delayed hypersensitivity reactions, more
so than the surrounding normal skin. A
marked inflammatory response occurs
in the tumour and it often regresses.
This approach has been used mainly on
basal cell carcinoma where it has had
startling success. However, it is rather
difficult to see how this form of treatment
merits the title " immunotherapy ". The
injection of other agents such as BCG
(Morton et al., 1970) and vaccinia (Hunter-
Craig et al., 1970) into cutaneous tumours
and their subsequent regression seems
to imply that the treatment is probably
the result of intratumoral inflammation
rather than any specific immunological
process directed against tumour antigens.
The Prospectsfor Immunotherapy of
Human Cancer
When assessing the immediate pros-
pects for some form of immunological
attack on malignant disease, the basis
for any programme will have to take
into account the clinical experience
accumulated over the years but will also
have to have a sound theoretical basis
in animal experimentation. The exten-
sive experimental work in this field in
recent years is too vast to be reviewed
here. However, the following is a brief
summary of some possible ways in which
the various immunological procedures
may be used in the nearfuture.
Passive immunotherapy. The cumula-
tive clinical experience so far gained from
serotherapy is far from promising. Both
specific and non-specific passive treatment
are potentially harmful and ofvery limited
use even in experimental animals. The
role of circulating antibody in host
resistance to tumours is unclear but it is
unlikely that cytotoxic immunoglobulins
reach the extracellular fluid in any
appreciable concentration. However,
they may be important in inhibiting
blood-borne spread of tumour cells. Their
brief sojourn in a high concentration of
serum antibody may be enough to kill
them and prevent metastases developing.
Thus, either the induction or passive
transfer of xenogeneic anti-tumour anti-
body could be used, say during surgery,
to prevent dissemination of live cells.
Adoptive immunotherapy. The adop-
tive transfer of the cellular components
of an immune response is at first sight a
rational and promising approach despite
the absence of any notable success so far
in the clinical field. This approach in
experimental animals can be ofvalue.
The administration ofmassive numbers
of allogeneic lymphoid cells will obviously
be a dangerous procedure likely to be
complicated by the development of graft-
versus-host disease. However, there are
several ways in which such a complica-
tion could be prevented. Simple irradia-
tion of the lymphocytes, while destroying
their ability to mount the GVH reaction,
would not inhibit their ability to transfer
an immune response. The use ofextracts
of immune lymphocytes may be of value.
Alexander and his colleagues (1967) have
shown that nucleic acids (probably RNA)
from immune lymphoid cells can be used
as a successful form of immunotherapy of
chemically-induced rat tumours. Other
factors produced by lymphocytes such as
" transfer factor " (a low molecular weight
substance produced by lymphocytes
which is alleged to confer specific immune
reactions from one individual to another)
may have a similar role to play. It
may be possible in the near future to sen-
sitize the patient's lymphocytes in tissue
culture by confronting them with tumour
cells; then the stimulated cells could be
infused back into the patient.
Active immunotherapy.-Exposure to
tumour antigen in one way or another will
probably continue to be a popular method,
mainly because it is a relatively simple
procedure. Injection of crude tumour
macerates or cell suspensions will no
doubt be superseded by the use of con-
centrated and relatively pure prepara-
tions of antigen. Such membrane anti-
gens will still be weak immunogens.
Methods of increasing the immunogenicity
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of such tumour antigen preparations with
a variety of helper determinants such as
xenogeneic globulins or xenogeneic cell
wall antigens (heterokaryons) are under
examination at the moment(Watkinsetal.,
1969). Treatment of the cells with en-
zymes such as n-acetyl neuraminine acid
hydrolase is also being studied as a method
of enhancing the immunogenicity of tu-
mour cells (Simmons et al., 1971). Non-
specific active immunotherapy is under
clinical investigation and its extended use
will depend on the discovery and isolation
of more powerful and less toxic agents.
The development of an effective form of
active immunotherapy willprobably paral-
lel our increasing ability to manipulate the
immune response.
POTENTIAL DANGERS OF IMMUNOTHERAPY
As with all forms of therapy, any
hypothetical immunological cancer treat-
ment will have its hypothetical hazards.
Perhaps the most worrying of such
hazards is immunological enhancement of
tumour growth. This is a phenomenon
originally described in an allogeneic
tumour system (Kaliss, 1958) in which the
administration of allogeneic antibody will
protect the tumour and its growth rate
can be enhanced.
The mechanism of this protection is
still not fully understood. Antibody may
inhibit cell-mediated cell destruction in
one of three ways afferent, central or
efferent. The bulk of evidence suggests
that efferent inhibition by coating the
tumour cells and preventing contact
with immune effector cells is improbable.
Some form ofcentral (or afferent) blockade
of lymphocyte function is probably
involved. Immunological enhancement
although readily induced across a histo-
compatibility barrier, can only be repro-
duced in syngeneic tumours with con-
siderable difficulty. In the series of
clinical immunotherapy methods so far
published most authors have emphasized
the lack of harm from their treatments.
Only in one very early series was the
possibility of accelerated tumour growth
suggested (Risley, 1911). This potential
problem will be better understood when
we have more appropriate animal models
for human immunotherapy programmes.
One possible hazard likely to arise
during the use of allogeneic adoptive
(cellular) therapy is that of graft-versus-
host disease. The administration of large
numbers of allogeneic immunologically
competent cells to patients whose immune
reactivity may be depressed may lead to
such a reaction. The transplanted lym-
phocytes survive the host's attempts at
rejection, consequently mounting a reac-
tion against the host's transplantation
antigens.
One further potential complication of
active immunotherapy given over long
periods may ensue as the result of pro-
longed overstimulation of the RES. It
is possible that such chronic stimulation
could lead to amyloidosis, autoimmune
diseases and possibly the development of
malignant reticuloses.
IMMUNOTHERAPY AS PART OF A
COMBINATION TREATMENT OF
CANCER
When faced with an established
tumour, the immune response, even when
heightened by any of the techniques we
have at our disposal, may well be too
feeble to ablate all the malignant cells.
The host responses have to cope with
replicating weak antigens. An immuno-
logical attack on an established tumour
appears to be unable to inhibit its pro-
gressive growth and consequently, the
tumour-host balance in the patient with
established cancer is inexorably tilted in
the favour of the tumour. However,
such a hypothetical balance may be
temporarily reversed by conventional
treatment methods such as radicalsurgery,
irradiation and cytotoxic chemotherapy.
It is at such a time that immunological
treatment may be able to maintain the
balance in favour of the patient by adding
its albeit meagre weight, and ablate
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those few residual cells that would other-
wise inevitably lead to tumour recurrence.
Immunotherapy, by virtue ofitsspecificity
in attack, may be the vital last straw that
breaks the camel's back and thereby
lead to complete and lasting regression.
In 1929, Woglom concluded his survey
of tumour immunology in a pessimistic
vein: " Nothing may accordingly be
hoped for at present in respect to a
successful therapy from this direction".
Extensive clinical experience in attempt-
ing to develop tumour immunotherapy has
provided very little reason to allay such
pessimism. Despite this lack of clinical
evidence, there is at present a rising tide
of renewed optimism. The demonstra-
tion of antigenic systems in animal and
human tumours certainly provides a
sound basis for our optimism. However,
before rushing headlong into extensive
clinical immunotherapy programmes and
thereby possibly putting the clock back
80 years, there seem to be one or
two essential prerequisites for the design
of rational therapeutic protocols. The
development of animal models for tumour
immunotherapy must be a first priority.
The development ofcomplex combinations
of immunotherapy in conjunction with
surgery, chemotherapy or irradiation still
require very careful animal experimenta-
tion before we can have any clear idea of
what to do to patients. Furthermore,
in order to use any form of therapy with
precision andinappropriate circumstances,
it is important that quantitative informa-
tion is available about its effects. Such
quantitative techniques for measuring
specific anti-tumour host reactions and the
effects of therapy on such reactions will
be needed in order to provide some degree
ofcontrol over the treatment.
The clinical evaluation of the effects of
immunotherapy will be an even more
complex problem. In order to establish
a clear role, if any, for the use of immuno-
logical treatment in the control of cancer,
large-scale trials with carefully controlled
groups will be mandatory. Furthermore,
the immunological treatment will most
likely play a minor role in a complex
combination of treatments, thus making
the design of adequate clinical trials
extremely difficult.
One further remark from Woglom's
review which remains pertinent to those
involved in developing clinical trials of
tumour immunotherapy: " It is perhaps
significant that the greater the experience
of the investigator the less successful are
theresults apt to be ". Haphazard clinical
adventures in immunological treatment
have so farbeen unsuccessful and generally
seem to confirm this remark.
The cautious inclusion of immunologi-
cal treatment into the repertoire of the
clinical oncologist and scrupulous investi-
gation oftheir effects mayeventually allow
us to find a role for immunotherapy as
part of a strategic attack on the malignant
cell.
This work hasbeensupportedbygrants
made to the Chester Beatty Research
Institute by the Cancer Research Cam-
paign and the Medical Research Council.
I am indebted to Professor Peter
Alexander for his advice and encourage-
ment.
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